Brivaracetam Genetic Epilepsy: What a 20-Study Review Found
This explainer summarizes research on brivaracetam genetic epilepsy outcomes in people with GGEs and DEEs.
Source: Neurology and therapy
Summary
What was studied
This systematic review and meta-analysis combined findings from 20 studies of brivaracetam, an antiseizure medicine, in people with genetic generalized epilepsies (GGEs) and developmental and/or epileptic encephalopathies (DEEs). Researchers searched for studies published through October 19, 2026.
They estimated rates of at least a 50% reduction in seizure frequency, seizure freedom, continued treatment, and unwanted medical events. They also examined results separately for GGEs, juvenile myoclonic epilepsy (JME), and DEEs.
What they found
Across the included studies, the pooled rate of at least a 50% reduction in seizure frequency was 50% (95% confidence interval [CI] 35โ66%), and the pooled seizure-freedom rate was 22% (95% CI 11โ39%). These estimates combine outcomes reported across studies; they do not establish how much of the observed improvement was caused by brivaracetam.
For people with GGEs, the pooled rate of at least a 50% seizure reduction was 61% (95% CI 41โ78%), and the pooled seizure-freedom rate was 38% (95% CI 17โ65%). In the JME subgroup, the corresponding pooled rates were 77% (95% CI 45โ93%) and 67% (95% CI 57โ75%). For people with DEEs, the pooled rate of at least a 50% seizure reduction was 44% (95% CI 24โ66%).
The pooled 12-month retention rate was 62% (95% CI 42โ79%). The pooled proportion experiencing any treatment-emergent adverse event was 37% (95% CI 19โ60%), while 7% discontinued brivaracetam because of these events (95% CI 3โ19%).
Limits of the evidence
The evidence came from small studies that mostly looked back at existing patient records. Patients and clinical circumstances varied substantially across studies, and many confidence intervals were wide. These pooled rates do not establish how brivaracetam compares with other medicines or no treatment, or prove that it works better in JME than in other epilepsy groups.
The abstract does not report the total number or ages of participants, the length of time used to define seizure freedom, the specific unwanted events, or a seizure-freedom estimate for DEEs. Events occurring after treatment starts are not necessarily caused by the medicine.
For families and caregivers
The findings suggest that brivaracetam may help some people with these epilepsy types reduce seizures or become seizure-free. The reported results were particularly encouraging in JME, while evidence for DEEs remained less certain. These pooled results cannot predict an individual person's benefit or unwanted effects.
What to watch next
Larger studies that follow patients forward in time, compare treatments, and use clear, consistent outcome definitions would help address the current evidence limitations.
Terms in this summary
- Genetic generalized epilepsies (GGEs)
- A group of epilepsies linked to genetic factors, with seizures involving networks on both sides of the brain.
- Developmental and/or epileptic encephalopathies (DEEs)
- Conditions in which an underlying disorder, epileptic activity, or both contribute to developmental difficulties.
- Juvenile myoclonic epilepsy (JME)
- A type of genetic generalized epilepsy that includes brief, sudden muscle jerks.
- Pooled estimate
- A result calculated by combining findings from multiple studies.
- 95% confidence interval (CI)
- A range that shows uncertainty around an estimate; wider ranges mean less precision.
- Responder rate
- In this review, the percentage of patients whose seizure frequency fell by at least 50%.
- Retention rate
- The percentage of patients still taking a medicine at a specified time.
- Treatment-emergent adverse event
- An unwanted medical event that appears or worsens after treatment begins, whether or not the treatment caused it.
Suggest a correction ยท Editorial standards
Free: Seizure First Aid Quick Guide (PDF)
Plus one plain-language weekly digest of new epilepsy research.
Unsubscribe anytime. No medical advice.